Finanzen von Agios Pharmaceuticals, Inc. (AGIO)AGIOAgios Pharmaceuticals, Inc.

Evaluating the bottom line, Agios Pharmaceuticals, Inc. maintains a gross margin of 93.30%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -247.07%, while the net margin is -225.06%. These profitability ratios, combined with a Return on Equity (ROE) of -34.34%, provide a clear picture of how effectively AGIO converts its operational activities into shareholder value.

In the context of the broader market, AGIO competes directly with industry leaders such as SRPT and ZYME. With a market capitalization of $1.90B, it holds a significant position in the sector. When comparing efficiency, AGIO's gross margin of 93.30% stands against SRPT's 62.59% and ZYME's 100.00%. Such benchmarking helps identify whether Agios Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Agios has shown a strong gross margin of 93.30% in Q2 2026, indicating effective cost management despite ongoing losses. The company has also maintained a healthy current ratio of 10.22, suggesting good short-term financial health.